Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors
Chemistry & Biodiversity · 2024-12 · 21 (12)
DOI: 10.1002/cbdv.202401697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 23.10.2024. Verfasst von Maria Fesatidou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Drug Design, SARS-CoV-2, Thiazolidines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HEAL-Link, Hellenic Academic Libraries Link.
Abstract (Originalsprache)
HIV‐1 remains a major health problem worldwide since the virus has developed drug‐resistant strains, so, the need for novel agents is urgent. The protein reverse transcriptase plays fundamental role in the viruses’ replication cycle. FDA approved Delavirdine bearing a sulfonamide moiety, while thiazolidinone has demonstrated significant anti‐HIV activity as a core heterocycle or derivative of substituted heterocycles. In this study, thirty new thiazolidinone derivatives (series A, B and C) bearing sulfonamide group were designed, synthesized and evaluated for their HIV‐1 RT inhibition activity predicted by computer program PASS taking into account the best features of available NNRTIs as well as against SARS‐COV‐2 main protease. Seven compounds showed good anti‐HIV inhibitory activity, with two of them, C1 and C2 being better (IC 50 0.18 μΜ & 0.12 μΜ respectively) than the reference drug nevirapine (IC 50 0.31 μΜ). The evaluation of molecules to inhibit the main protease revealed that 6 of the synthesized compounds exhibited excellent to moderate activity with two of them (B4 and B10) having better IC 50 values (0.15 & 0.19 μΜ respectively) than the reference inhibitor GC376 (IC 50 0.439 μΜ). The docking studies is coincides with experimental results, showing good binding mode to both enzymes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.
ORCID-Profile: Athina Geronikaki
Förderung
- HEAL-Link
- Hellenic Academic Libraries Link
Zitieren
APA
Fesatidou, M., Petrou, A., & Geronikaki, A. (2024). Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors. Chemistry & Biodiversity, 21(12). https://doi.org/10.1002/cbdv.202401697
Vancouver
Fesatidou M, Petrou A, Geronikaki A. Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors. Chemistry & Biodiversity. 2024;21(12). doi:10.1002/cbdv.202401697
BibTeX
@article{Fesatidou2024,
author = {Fesatidou, Maria and Petrou, Anthi and Geronikaki, Athina},
title = {Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors},
journal = {Chemistry & Biodiversity},
year = {2024},
volume = {21},
number = {12},
doi = {10.1002/cbdv.202401697}
}
EUVIMED